Literature DB >> 12852762

A computational model of binding thermodynamics: the design of cyclin-dependent kinase 2 inhibitors.

Peter A Sims1, Chung F Wong, J Andrew McCammon.   

Abstract

The cyclin-dependent protein kinases are important targets in drug discovery because of their role in cell cycle regulation. In this computational study, we have applied a continuum solvent model to study the interactions between cyclin-dependent kinase 2 (CDK2) and analogues of the clinically tested anticancer agent flavopiridol. The continuum solvent model uses Coulomb's law to account for direct electrostatic interactions, solves the Poisson equation to obtain the electrostatic contributions to solvation energy, and calculates scaled solvent-accessible surface area to account for hydrophobic interactions. The computed free energy of binding gauges the strength of protein-ligand interactions. Our model was first validated through a study on the binding of a number of flavopiridol derivatives to CDK2, and its ability to identify potent inhibitors was observed. The model was then used to aid in the design of novel CDK2 inhibitors with the aid of a computational sensitivity analysis. Some of these hypothetical structures could be significantly more potent than the lead compound flavopiridol. We applied two approaches to gain insights into designing selective inhibitors. One relied on the comparative analysis of the binding pocket for several hundred protein kinases to identify the parts of a lead compound whose modifications might lead to selective compounds. The other was based on building and using homology models for energy calculations. The homology models appear to be able to classify ligand potency into groups but cannot yet give reliable quantitative results.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12852762     DOI: 10.1021/jm0205043

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Study of the inhibition of cyclin-dependent kinases with roscovitine and indirubin-3'-oxime from molecular dynamics simulations.

Authors:  Bing Zhang; Vincent B C Tan; Kian Meng Lim; Tong Earn Tay; Shulin Zhuang
Journal:  J Mol Model       Date:  2006-06-13       Impact factor: 1.810

2.  Molecular dynamics simulations on the inhibition of cyclin-dependent kinases 2 and 5 in the presence of activators.

Authors:  Bing Zhang; Vincent B C Tan; Kian Meng Lim; Tong Earn Tay
Journal:  J Comput Aided Mol Des       Date:  2006-10-13       Impact factor: 3.686

3.  Study of a ligand complexed with Cdk2/Cdk4 by computer simulation.

Authors:  Yongjun Jiang; Jianwei Zou; Chunshan Gui
Journal:  J Mol Model       Date:  2005-06-01       Impact factor: 1.810

4.  How to choose relevant multiple receptor conformations for virtual screening: a test case of Cdk2 and normal mode analysis.

Authors:  Olivier Sperandio; Liliane Mouawad; Eulalie Pinto; Bruno O Villoutreix; David Perahia; Maria A Miteva
Journal:  Eur Biophys J       Date:  2010-03-18       Impact factor: 1.733

5.  A computational study of the protein-ligand interactions in CDK2 inhibitors: using quantum mechanics/molecular mechanics interaction energy as a predictor of the biological activity.

Authors:  Jans H Alzate-Morales; Renato Contreras; Alejandro Soriano; Iñaki Tuñon; Estanislao Silla
Journal:  Biophys J       Date:  2006-11-03       Impact factor: 4.033

6.  Evaluation of the utility of homology models in high throughput docking.

Authors:  Philippe Ferrara; Edgar Jacoby
Journal:  J Mol Model       Date:  2007-05-09       Impact factor: 1.810

Review 7.  Advances and challenges in protein-ligand docking.

Authors:  Sheng-You Huang; Xiaoqin Zou
Journal:  Int J Mol Sci       Date:  2010-08-18       Impact factor: 5.923

Review 8.  Insights on Structural Characteristics and Ligand Binding Mechanisms of CDK2.

Authors:  Yan Li; Jingxiao Zhang; Weimin Gao; Lilei Zhang; Yanqiu Pan; Shuwei Zhang; Yonghua Wang
Journal:  Int J Mol Sci       Date:  2015-04-24       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.